Swedish study indicates most protection is achieved after the second dose, but a third dose reduces infection risk further.
The quadrivalent human papillomavirus (HPV) vaccine provides protection against HPV types 6 and 11 (which cause most genital warts) as well as oncogenic HPV types 16 and 18. The recommended immunization schedule calls for vaccine administration at 0, 2, and 6 months; however, many women do not receive all three doses. Using combined data from nationwide registries in Sweden, investigators assessed the effectiveness of one, two, or three doses of HPV vaccine for prevention of genital warts in girls and women (age range, 10–24 years). In a cohort of >1 million women followed for a mean of 3.8 years, more than 300,000 received the vaccine. Women with diagnoses of genital warts prior to vaccination were excluded.
Compared with risk for genital w…
Reviewing Author
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)
DisclosuresConsultant/Advisory BoardAicuris; Bayer; GSK; Innovative Molecules; Merck; MAPP Biopharmaceutical (Safety Monitoring Committee)
RoyaltiesUpToDate
Grant/Research SupportNIH/National Institute of Allergy and Infectious Diseases; GSK; Moderna; Assembly Biomedical; Aicuris
Editorial BoardsSexually Transmitted Diseases; Sexually Transmitted Infections; Journal of Infectious Diseases
Leadership PositionsID Division Chiefs Community of Practice (At-Large Member)